This is a program of the U.S. Department of Health and Human Services, Office of Public Health Emergency Medical Countermeasures, and the National Institutes of Health. The program is coordinated by NIAID, with the involvement of the National Cancer Institute.
The Radiation and Nuclear Countermeasures Program, DAIT, NIAID is participating in the following Program Announcements: PAR-16-093, Improvement of Animal Models for Stem Cell-Based Regenerative Medicine (R01); PAR-16-094, Improvement of Animal Models for Stem Cell-Based Regenerative Medicine (R21). Standard NIH Receipt dates for R01 and R21s apply.
BAA-NIAID-DAIT-NIHAI2015042: Development of Radiation/Nuclear Medical Countermeasures or Biodosimetry Devices. Response date – March 22, 2016
RFA-HL-16-003: Collaborative Projects to Accelerate Research in Organ Fibrosis (R01) (co-funded by NIAID)—Receipt date Oct. 21, 2016
Pegfilgrastim Approved for Treatment of Acute Radiation Syndrome—Dec. 3, 2015
All Radiological and Nuclear Threats News Releases
News From NIAID-Supported Institutions
Last Updated February 12, 2016